phosphorylcholine has been researched along with interleukin-8 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baudhuin, LM; Hong, G; Mok, SC; Morrison, BH; Schwartz, BM; Wu, W; Xiao, YJ; Xu, Y | 1 |
| Brauner, A; Chromek, M; Dadfar, E; Kaca, W; Rabbani, H; Stankowska, D | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC; Pietri, JE; Tepper, CG | 1 |
3 other study(ies) available for phosphorylcholine and interleukin-8
| Article | Year |
|---|---|
Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.
Topics: Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Lysophospholipids; Ovarian Neoplasms; Phosphorylcholine; RNA, Messenger; Sphingosine; Tumor Cells, Cultured; Up-Regulation | 2001 |
Interleukin-8 response in cells from the human urinary tract induced by lipopolysaccharides of Proteus mirabilis O3 and O18.
Topics: Cell Line; Epithelial Cells; Flow Cytometry; Humans; Interleukin-8; Kidney; Lipopolysaccharide Receptors; Lipopolysaccharides; Monocytes; O Antigens; Phosphorylcholine; Proteus mirabilis; RNA, Messenger; Urinary Bladder | 2005 |
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-8; Kidney Neoplasms; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases | 2012 |